Media

BOTHELL, WA–(Marketwired – Dec 12, 2013) – Borneo Resource Investments Ltd. (OTCQB: BRNE) (the “Company” or “Borneo”), a mining company that mines gold and develops producing gold mines as well as coal mining properties in Indonesia, today announced it has, through its subsidiary PT Puncak Kalabat, finalized the purchase of a producing gold mining property for $250,000, including an initial $150,000 payment in cash and two subsequent payments of $50,000 each. Targeted funding for the acquisition was provided by a private investor and current shareholder of the Company through a 5-year loan with an annual interest rate of 5%. The term loan has no conversion provision and no warrants were attached.

The acquired property, with the project name of Ratatotok South, is located near the village of Ratatotok in the Southeast Minahasa Regency of the North Sulawesi Province of Indonesia. The property is adjacent to the southern border of one of Borneo’s other gold mining properties, Ratatotok. Ratatotok South comes with assets including a stockpile of ore on site ready for processing, as well as significant infrastructure and equipment. Borneo plans to immediately begin supplemental excavation, with initial production slated to commence before the end of December 2013.

Gold production at Ratatotok South would further supplement Borneo’s current production at its first producing gold mine, Talawaan, which completed its first full quarter of production in the third quarter of 2013. Borneo reported over $500,000 in revenues and over $40,000 in net income in the third quarter of 2013 based on mining at Talawaan alone.

The Ratatotok South property is approximately 8.5 hectares in size and is located in the middle of a well-established gold reef structure. Significant reserve assessment work for the property was completed by the seller, who commissioned an independent mining geologist. The analysis involved a comprehensive set of drill tests throughout the property. These tests show ore grades ranging from 3-15 grams per ton. Borneo’s in-house geologist estimates that the ore body extends from approximately 15 cm below the surface to around 100 meters in depth and covers the entire property.

Significant infrastructure situated on the property was purchased as part of the transaction price including an ore crusher and other ore processing equipment.

“This is a significant acquisition for us that will further boost our gold production levels, revenues and contribute to gross profits. Based on our analysis, processed ore at this site may produce 99% pure gold,” commented Borneo CEO Nils Ollquist.

Mr. Ollquist went on to say, “The structure and quality of the ore body on the property means that the extraction process used at Ratatotok South will be significantly less labor intensive and at a lower cost than the extraction method employed at our Talawaan property.”

“Having Ratatotok South strategically located, with all of its infrastructure and equipment, adjacent to Ratatotok which we plan on mining in the near future, increases the value of Ratatotok and accelerates our timeline for mining all three of our current gold properties. We are particularly pleased with how we financed this transaction. The lender of the $150,000 note is a current shareholder of the Company. We believe this is an investment that will generate a very favorable ROI for Borneo,” Ollquist concluded.

About Borneo Resource Investments Ltd.

Borneo Resource Investments Ltd. (OTCQB: BRNE) is a mining company that mines gold and develops producing gold mines as well as coal mining properties in the Republic of Indonesia. Borneo’s current assets include three gold properties, two of which are producing gold. Cash flow-producing investments in gold properties help fund Borneo’s operations and investments in gold, while the Company develops high value, longer-term investments in thermal “coal concessions,” which are properties that can be mined for coal. Borneo currently has one coal concession in the Borneo region of Indonesia. Indonesia was the 8th largest gold producing nation in 2012 and the world’s largest exporter of coal, with $25 billion exported in 2012.

JERUSALEM, December 10, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received allowance for a key patent from the Israeli Patent Office. The patent, entitled “Methods and Compositions for Oral Administration of Exenatide,” covers oral exenatide compositions made using the company’s proprietary technology.

Exenatide, a GLP-1 analog, is currently only marketed in injectable form, and is indicated for the treatment of Type 2 diabetes. Exenatide has an excellent safety profile and a plethora of positive medicinal effects including weight loss and improved pancreatic cell function.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate SupinoxinTM (RX-5902). Rexahn had previously received a composition of matter patent from the United Stated Patent and Trademark Office covering the structure of Supinoxin.

“We are progressing on schedule with our Phase I dose-escalation clinical trial for Supinoxin in cancer patients with solid cancer tumors. Having initiated patient enrollment in August, we expect data in the first half of 2014, which will help inform the study design for future Phase II trials on Supinoxin,” stated Rexahn CEO Peter D. Suzdak, Ph.D.

“We are committed to developing cancer treatments that specifically target cancer cells, excluding healthy tissue, so that cancer can be treated with increased efficacy and reduced toxicity. Strengthening our IP portfolio as we advance in our clinical trials adds critical value to our company,” added Dr. Suzdak.

In-vitro studies have shown that Supinoxin reduces the spread of 18 different human cancer cells lines. Supinoxin has also shown that it can eliminate cancer cells which were resistant to other widely used cancer drugs including docetaxel, cisplatin and gemcitabine. Supinoxin is an orally available new chemical entity exhibiting potent antitumor properties in several types of tumors and has also show strong anti-proliferative activity against known anti-cancer drug-resistant cancer cells, and a synergistic effect with known anti-cancer drugs as well.

About SupinoxinTM (RX-5902)

Supinoxin is an orally administered, first-in-class, small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68). P-p68, which is selectively expressed in cancer cells but absent in normal tissue, increases the activity of multiple cancer related genes including cyclin D1, c-jun and c-myc, and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been observed in solid tumors such as melanoma, colon, ovarian and lung.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and SupinoxinTM (RX-5902), and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

The holiday windows in New York City are so spectacular they are guaranteed to bring out the holiday spirit in even the most cynical of new yorkers. This year we braved the crowds and the cold to give you a front row look at some of the most breathtaking displays we’ve ever seen behind glass. This year NYC retailers are taking you around the world, through the holidays, to the future, and back into time; with some of the windows even letting shoppers become part of the show. CorporateProfile/ClearVISION host Annamaria Chen is guiding viewers through the best 2013 holiday windows NYC has to offer; including Saks Fifth Avenue, Barneys, Lord & Taylor, Bloomindale’s, Bergdorf Goodman, Macy’s, Tiffany & Co., and Henri Bendel.

They say “what happens in Vegas stays in Vegas” but that’s not the case with the Sugar Factory. This world renowned sweet spot has made its way to 46 Gansevoort Street in the Meatpacking District and they aren’t just selling candy.

If you like your food sweet, your drinks smoking, and your candy sparkling; Sugar Factory American Brasserie is the place for you. Corporate Profile/ClearVISION Host Annamaria Chen sits down with owner Tom Recine, and then rolls up her sleeves behind the bar and in the kitchen to learn how to make their 60 ounce Lollipop Passion Goblet and a King Kong Ice Cream Sundae big enough for 12.

Sugar Factory American Brasserie
46 Gansevoort St, New York, NY 10014
www.SugarFactory.com

FORT WORTH, TX–(Marketwired – Dec 10, 2013) – Good Earth Energy Conservation, Inc., a subsidiary of Numbeer, Inc. (OTCQB: NUMB) and provider of electric fleet vehicles for the essential services market, announced today it has received a purchase order for one Firefly® Essential Service Vehicle (ESV) from the City of Berkeley, California.

The made-in-the-USA 3-wheeled energy efficient Firefly® is scheduled for delivery to Berkeley in the first quarter of 2014. This marks the first Firefly® purchase by the City of Berkeley, which will use the electric vehicle for parking enforcement. Berkeley currently has approximately 50 vehicles in its parking enforcement fleet.

This sale was made through one of Good Earth Energy Conservation’s growing network of dealers, Santa Clara, California-based Turf and Industrial Equipment Company. “This purchase order from the City of Berkeley is another indicator of the interest we are seeing for the Firefly® in Northern California. We currently have an installed base of customers throughout our region and once we present the economic and environmental benefits of the Firefly® to our customers, we’re seeing immediate interest in purchases. We expect to sell a lot more Firefly® ESVs in the future. They make economic sense for the customer,” stated John Matheny, President of Turf and Industrial Equipment Company.

Based on usage estimates and relative fuel prices for service vehicles, the Firefly® can create annual cost savings of $8,000 – $10,000, as compared to the cost of using a conventional gas-powered vehicle.

“Berkeley is committed to sustainable energy and development. We look forward to integrating the zero-emissions Firefly® into our parking enforcement fleet to reduce our city’s operating costs and improve our energy efficiency,” commented Noel Pinto, Parking Enforcement Manager, City of Berkeley.

Good Earth Energy Conversation CEO James Emmons added, “Parking enforcement is a usage application which our Firefly® meets perfectly. Municipalities use parking enforcement vehicles an average of 40 hours per week. Traditional gas powered vehicles are burning fuel at a national cost average of over $3.50 per gallon, while emitting carbon dioxide, and causing wear and tear on the vehicles, which will require more service and maintenance, thus creating constantly rising operating costs. The Firefly® has fewer moving parts, requires less maintenance, is a zero emissions electric vehicle and costs less than $.02 per mile to operate.”

To learn more about the Firefly® please see the following video: http://fireflyesv.com/work/black-whites/

About Firefly® ESV

The Company’s 3-wheeled Firefly® ESV is engineered and built entirely in the United States. The Firefly uses the longer life cycle lithium iron phosphate battery that has an eight-hour charger compatible with a standard 110v or 220v outlet. The Firefly® is capable of up to 60+ and 90+ miles per charge (extended range model) and performance speeds of up to 45 mph. The basic design of the Firefly® also permits tailoring to the specific requirements of the varying market segments within the essential services market. The vehicle’s modular design will facilitate the export of vehicle kits which can be easily assembled and sold in emerging markets, such as China and other international markets.

For more information about the Company, please visit http://www.FireFlyESV.com

Corporate Profile/ClearVISION Host Annamaria Chen sits down with Blackfish Director Gabriela Cowperthwaite to discuss her critically acclaimed film Blackfish. Gabriela talks about her inspiration, shocking discoveries, Pixar rumors, and her hopes for the future of SeaWorld.

About The Film:

Blackfish tells the story of Tilikum, a performing killer whale that killed several people while in captivity. Along the way, director-producer Gabriela Cowperthwaite compiles shocking footage and emotional interviews to explore the creature’s extraordinary nature, the species’ cruel treatment in captivity, the lives and losses of the trainers and the pressures brought to bear by the multi-billion dollar sea-park industry.

VIENNA, Va.–(BUSINESS WIRE)–

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Bosnia and Herzegovina is the 10th country into which CEL-SCI has now expanded its global Phase III trial. This also marks the Company’s milestone in receiving approval to commence accrual in one-half the number of countries in the currently planned expansion of the study. The trial is expected to expand into a total of approximately 100 clinical centers in 20 countries. CEL-SCI expects to enroll approximately 30 patients in Bosnia and Herzegovina through three clinical centers.

Multikine is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved by regulatory agencies (e.g. FDA) for use following completion of CEL-SCI’s clinical development program, Multikine would become an additional and different kind of therapy in the fight against cancer: one that aims to employ our body’s natural ability to fight tumors.

CEL-SCI is currently accelerating enrollment in its Phase III clinical trial for Multikine by adding a large number of clinical centers. In addition to these centers, the trial also benefits from clinical centers in CEL-SCI’s partners’ territories, Teva Pharmaceuticals in Israel and Orient Europharma in Taiwan.

“We are pleased with the accelerating pace at which new clinical centers and countries, which will participate in our study, are being added. From this we expect to see a fast pick-up in the number of patients enrolled in the study. We are aiming to complete enrollments of subjects in the second half of 2015. CEL-SCI offers a potential first-line approach to cancer treatment that employs the body’s own immune system, before the current standard of care, which includes surgery plus radiation therapy or surgery and combined radiochemotherapy, is used,” stated CEL-SCI CEO Geert Kersten.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant, 10% improvement in overall survival of enrolled patients who are treated with Multikine plus Standard of Care (SOC) vs. subjects who are treated with SOC only. Multikine is intended to create an anti-tumor immune response to reduce local / regional tumor recurrence and thereby increase the survival rate of these patients.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Annamaria Stewart (Chen) takes viewers on an interactive tour of American Girl Place New York. At American Girl Place, girls can not only pick out a new doll, they can bring their favorite for a new hairstyle at the Doll Hair Salon, get a check-up at the Doll Hospital, and treat her to a special meal at the American Girl Cafe.

American Girl Place New York
609 Fifth Avenue at 49th Street, New York, NY 10017
www.AmericanGirl.com